Joy C. Yang

University of California, Davis — United States

Medicine · Health Sciences

39h-index6.1kcitations218works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(130), Cancer, Lipids, and Metabolism(53), Estrogen and related hormone effects(25), Cancer, Hypoxia, and Metabolism(18), Metabolomics and Mass Spectrometry Studies(18)

Publications218 total

Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer
Cancers·2025Open Access
Abstract 4491: HSP70 leverages STUB1 to modulate N-Myc protein turnover in lethal prostate cancer
Cancer Research·2025
Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer
Oncogene·2025Open Access
PD10-10 THE ROLE OF MACROPHAGES IN CONFERRING ANTIANDROGEN RESISTANCE AND IMMUNE EVASION IN CASTRATION-RESISTANT PROSTATE CANCER
The Journal of Urology·2025
IP26-23 DEGRADATION OF N-MYC BY HSP70 INHIBITION ENHANCES THE EFFECT OF ALISERTIB IN ADVANCED PROSTATE CANCER
The Journal of Urology·2025
MP32-06 HSP70 LEVERAGES STUB1 TO MODULATE N-MYC PROTEIN TURNOVER IN LETHAL PROSTATE CANCER
The Journal of Urology·2025
IP05-01 PLXND1 IS A POTENTIAL THERAPEUTIC TARGET AND PROGNOSTIC MARKER FOR NEUROENDOCRINE PROSTATE CANCER
The Journal of Urology·2025
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer
Nature Communications·2024· 6 citedOpen Access
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer
Oncogene·2024· 3 citedOpen Access
Novel Multiplexed High Throughput Screening of Selective Inhibitors for Drug-Metabolizing Enzymes Using Human Hepatocytes
The AAPS Journal·2024· 6 cited
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer
Research Square (Research Square)·2024Open Access
Abstract 3577: The role of PLXND1 in lineage plasticity and progression to neuroendocrine prostate cancer
Cancer Research·2024
Abstract 4567: Dual targeting of HSP70 and AURKA improves treatment in neuroendocrine prostate cancer
Cancer Research·2024
Entropy testing and its application to testing Bayesian networks
2024
895 Immunosuppressive signaling is activated in enzalutamide resistant prostate cancer
Regular and Young Investigator Award Abstracts·2023Open Access
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
Journal for ImmunoTherapy of Cancer·2023· 58 citedOpen Access
Abstract 3069: Targeting noncanonical Wnt5a signaling suppresses the neural lineage network and overcomes enzalutamide resistance in advanced prostate cancer
Cancer Research·2023
Abstract 5151: Enzalutamide resistance results in immunosuppressive alterations in prostate tumor immune microenvironment
Cancer Research·2023
Supplementary Figure 1 from NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants
2023Open Access
Data from Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Christopher P. Evans(42), Allen C. Gao(22), Chengfei Liu(15), Wei Lou(13), Hsing-Jien Kung(8), Alan P. Lombard(8), Cameron M. Armstrong(7), Nagalakshmi Nadiminty(6), Shu Ning(6), Clifford G. Tepper(5), Hong-Wu Chen(4), Liangren Liu(4), Leandro S. D’Abronzo(4), Pengfei Xu(4), Michael G. Rosenfeld(3), Lingru Xue(3), Ralph W. deVere White(3), Hao G. Nguyen(3), H-J Kung(3), Primo N. Lara(3)